secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALTEROLA BIOTECH INC. (—)
CIK:        0001442999
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001477932-25-004837
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alterola sells Phytanix to Protagenic, plans to deregister; directors resign
----------------------------------------------------------------------------

- Alterola and EMC2 sold 100% of Phytanix to Protagenic for Protagenic common and preferred stock; combined ownership: 35% existing Protagenic, 65% Alterola/EMC2.
- Alterola shareholders will be offered the option to swap ABTI shares for Protagenic shares; shareholder vote required by September 1, 2025.
- Alterola intends to terminate SEC registration and become a privately held company to reduce costs.
- Executive Chairman Tim Rogers, CEO David Hitchcock, CFO Nathan Thompson, and three independent directors resigned; Dominic Schiller and Colin Stott remain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1442999/000147793225004837/0001477932-25-004837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1442999/000147793225004837/abti_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-25-004837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer